Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies
Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President NEW YORK and ATHENS, Greece and SINGAPORE, Oct. 26, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the U.S. and European...
Covered in this story
Analyst targets on Biogen
- BMO Capital Markets: $229 → $220 by Oct 2027 · Market Perform via Investing.com
- Wolfe Research: $216 → $300 by Sep 2027 · Outperform via Yahoo Finance
- H.C. Wainwright: $203 → $251 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BIIB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Biogen →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.